

LENZ & STAEHELIN ADVISED CHORD THERAPEUTICS IN ITS SERIES A FINANCING

Posted on 2 November 2020



Category: [Deal & transactions](#)

Tags: [Chord Therapeutics](#), [David Ledermann](#), [Ex-Featured](#), [Federico Trabaldo Togna](#), [Floran Ponce](#), [Guy Vermeil](#), [Lenz & Staehelin](#), [Sevan Antreasyan](#)



Chord Therapeutics, a Geneva clinical stage biopharmaceutical company developing drugs for rare diseases, announced the closing of a USD 16 million Series A financing from leading healthcare investor **Omega Funds**. The financing will allow the company to progress its lead drug candidate, CRD1, a small molecule oral drug for the treatment of neuromyelitis optica spectrum disorders, through Phase 2 proof of concept clinical development.

The team

Lenz & Staehelin [advised Chord Therapeutics in its Series A financing](#). The team was led by Guy Vermeil (pictured) and included David Ledermann and Federico Trabaldo Togna (all Corporate, M&A), Florian Ponce (Tax), Sevan Antreasyan (Intellectual Property) and Prisca Cattaneo (Employment).